Europe Platelet Rich Plasma Market Size to Exceed USD 405.5 Mn by 2032

The Europe Platelet Rich Plasma Market, estimated at USD 147.0 Mn in 2025, is expected to exhibit a CAGR of 15.6% and reach USD 405.5 Mn by 2032.

The market growth is fueled by rising demand for advanced biotechnology solutions that improve healthcare outcomes, along with increasing adoption in areas such as drug development, diagnostics, and personalized medicine. Innovations in genomics, cell and gene therapies, and biomanufacturing, supported by strong R&D investments, are enhancing treatment effectiveness, efficiency, and accessibility. Furthermore, favorable regulatory support, strategic collaborations, and the growing focus on precision medicine are accelerating market expansion and opening new opportunities for industry participants.

Key market players are focusing on the adoption of organic growth strategies such as research and development, in order to strengthen their market presence and expand their product portfolio in the Europe Platelet Rich Plasma market. For instance, in August 2025, Regenerative Orthopaedics and Sports Medicine, a healthcare company, in collaboration with EmCyte Corporation, a biotechnology company, announced the initiation of clinical trial to study the he efficacy of one leukocyte-poor platelet-Rich plasma (LP-PRP) injection in treatment of hip OA (osteoarthritis).

Europe Platelet Rich Plasma Market – Impact of Coronavirus (COVID-19) Pandemic

The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2025, as "coronavirus disease 2025" or COVID-19. This virus spreads quickly, and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.

COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others faced problems regarding transportation of drugs from one place to another.

COVID-19 had a negative impact on the Europe Platelet Rich Plasma market, owing to decrease in cosmetic surgeries. For instance, according to news article published on October 12, 2025, in the website of Penningtons Manches Cooper LLP, a U.K.-based law firm, many healthcare professionals who perform elective or cosmetic surgery have been unable to provide their usual level of service, either because they have been focused on frontline work or hospitals have postponed all but the most critical inpatient appointments in order to slow the spread of the virus during the pandemic.

Europe Platelet Rich Plasma Market- Key Developments

Key players in the market are focused on product approvals from regulatory authorities to expand their product portfolio. For instance, in Februaury 2025, EmCyte Corporation, the world leader in platelet rich plasma and progenitor stem cell biologics, announces its FDA 510(k) clearance for its PurePRP Supraphysiologic Concentrating System for platelet Rich plasma.

Browse 16 Market Data Tables and 10 Figures spread through 120 Pages and in-depth TOC on “Europe Platelet Rich Plasma Market ”- Forecast to 2032 by PRP Type (Pure-PRP, Leukocyte-Rich PRP, Pure Platelet Rich Fibrin, Others), By Origin (Autologous, Allogeneic/Homologues), By Application (Orthopaedics, Cosmetic Surgery and Dermatology, Neurosurgery, Cardiothoracic Surgery, General Surgery, Urology, Others), and By Country (U.K., Germany, France, Italy, Spain, Russia, Rest of Europe)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/europe-platelet-rich-plasma-market-3346

Key Takeaways of the Europe Platelet Rich Plasma Market:

• Europe Platelet Rich Plasma market is expected to exhibit a CAGR of 15.6% during the forecast period, owing to increasing cases of various surgeries such as cosmetics and others. For instance, in for instance, in November 2025, according to the Harley Clinic Group Ltd, a Cosmetic Surgery Clinic based in London, U.K., reported that globally, over 10 million surgical and non-surgical cosmetic procedures are performed annually, whereas in 2025, approximately 15 thousand cosmetic procedures were performed alone in the U.K.
• Among PRP type, pure PRP segment is estimated to hold a dominant position in the Europe Platelet Rich Plasma market over the forecast period, owing to increasing adoption of organic growth strategies such as product approval by regulatory authorities. For instance, according to research study published by National Center for Biotechnology Information, in March 2025, PRP can be utilized as a new therapeutic approach for hair loss including androgenetic alopecia and female pattern baldness, either as a standalone treatment or as an adjunct to traditional therapy or hair transplantation. PRP is regarded as a risk-free, efficient, steroid-free alternative treatment for alopecia areata.
• Among country, U.K. is expected to be the dominant region in the Europe Platelet Rich Plasma market, owing to increasing incidence of muscle injuries. For instance, in February 2025, according to National Center for Biotechnology Information (NCBI), stated that the overall incidence of muscle injuries ranged from 33.33 in the under 18s age group to 83.33 in the under-20s age group in Europe.
• Major players operating in the Europe Platelet Rich Plasma market include Vivostat A/S, Estar Medical, CosmoFrance Inc., Kelly Harris Aesthetics, Arthrex, Inc., Terumo Corporation, T-Biotechnology Ltd. St., EmCyte Corporation, Johnson & Johnson Private Limited, Zimmer Biomet, PRP Concepts, ADVACARE PHARMA, Isto Biologics, Arthrex, Inc., Stryker, GLOFINN, Medira Ltd, Regen Lab SA, Estar Technologies Ltd.